4.160CAD-0.95%Mkt Cap: 94.75M $P/E: —1d ago
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and inter…
Industry Peers
Drug Manufacturers - Specialty & GenericIndicators:|
Key Statistics
Company
Market Cap94.75M $
Enterprise Value117.76M $
Revenue (TTM)40.59M $
Gross Profit33.08M $
Net Income (TTM)-9.05M $
Revenue/Share1.293 USD
Last Price4.160 CAD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees85
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-97.99
PEG—
EV/EBITDA9.32
EV/Revenue2.90
P/S2.33
P/B1.57
EPS (TTM)-0.45
EPS (Forward)-0.04
52W Range
0.001072% of range5.765
52W High5.765 CAD
52W Low0.0010 CAD
Profitability
Gross Margin81.83%
Oper. Margin-17.22%
EBITDA Margin31.12%
Profit Margin-22.40%
ROE-20.16%
ROA-9.04%
Growth
Revenue Growth1.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF12.48M $
CapEx (TTM)1.24M $
FCF Margin37.22%
FCF Yield15.95%
Net Debt23.02M $
Net Debt/EBITDA1.82
Balance Sheet
Debt/Equity0.81
Current Ratio1.00
Quick Ratio0.71
Book Value/Sh2.654 CAD
Cash/Share0.3940 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield1.73%
Payout Ratio0.00%
Ex-Div DateApr 27, 2023
Pay DateJun 15, 2023
Analyst Consensus
Rating—
Target (Mean)7.271 CAD
Upside (mean)+74.8%
Target Range4.587 CAD – 12.25 CAD
CAD4.587+74.8% to meanCAD12.25
# Analysts4
Ownership
Shares Out.31.27M
Float19.61M
Insiders0.53%
Institutions43.95%
Short Interest
Short Ratio3.5d
Short % Out.0.97%
Shares Short1.82K
Short (prev mo.)6.86K
Technical
SMA 504.431 (-6.1%)
SMA 2004.723 (-11.9%)
Beta0.86
S&P 52W Chg19.63%
Avg Vol (30d)22.89K
Avg Vol (10d)9.68K
Technical Indicators
RSI (14)41.0
MACD-0.0621
MACD Signal-0.0574
MACD Hist.-0.0046
BB Upper4.456 CAD
BB Middle4.279 CAD
BB Lower4.101 CAD
BB Width8.31%
ATR (14)0.1735 CAD
Vol Ratio (20d)0.50x